Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics (CADL)
NASDAQ:CADL
Holding CADL?
Track your performance easily
CADL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.08 - $14.60
Previous Close$8.75
Volume4.84M
Average Volume (3M)3.20M
Market Cap
$389.16M
Enterprise Value$388.63M
Total Cash (Recent Filing)$16.56M
Total Debt (Recent Filing)$16.02M
Price to Earnings (P/E)―
Beta-0.65
Next Earnings
Mar 27, 2025EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding32,475,537
10 Day Avg. Volume18,001,391
30 Day Avg. Volume3,201,329
Standard Deviation0.60
R-Squared0.00607
Alpha0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-18.62
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-8.42
Forecast
1Y Price Target
$19.00Price Target Upside117.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Candel Therapeutics News
Ownership Overview
22.78% Insiders
3.68% Mutual Funds
6.29% Other Institutional Investors
63.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CADL FAQ
What was Candel Therapeutics’s price range in the past 12 months?
Candel Therapeutics lowest stock price was $1.08 and its highest was $14.60 in the past 12 months.
What is Candel Therapeutics’s market cap?
Currently, no data Available
When is Candel Therapeutics’s upcoming earnings report date?
Candel Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 95 days.
How were Candel Therapeutics’s earnings last quarter?
Candel Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.33.
Is Candel Therapeutics overvalued?
According to Wall Street analysts Candel Therapeutics’s price is currently Undervalued.
Does Candel Therapeutics pay dividends?
Candel Therapeutics does not currently pay dividends.
What is Candel Therapeutics’s EPS estimate?
Candel Therapeutics’s EPS estimate is -$0.27.
How many shares outstanding does Candel Therapeutics have?
Candel Therapeutics has 44,475,536 shares outstanding.
What happened to Candel Therapeutics’s price movement after its last earnings report?
Candel Therapeutics reported an EPS of -$0.33 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.233%.
Which hedge fund is a major shareholder of Candel Therapeutics?
Among the largest hedge funds holding Candel Therapeutics’s share is Woodline Partners LP. It holds Candel Therapeutics’s shares valued at N/A.
---
Candel Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (117.14% Upside)
$19.00 (117.14% Upside)
Blogger Sentiment
Neutral
CADL Sentiment 50%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $6.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 48.9%
Last 30 Days ▲ 48.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
681.25%
12-Months-Change
Fundamentals
Return on Equity
-1344.47%
Trailing 12-Months
Asset Growth
-57.02%
Trailing 12-Months
Company Description
Candel Therapeutics
Candel Therapeutics Inc is a late clinical stage biopharmaceutical company. It is focused on helping patients fight cancer with oncolytic viral immunotherapies.
---
CADL Stock 12 Month Forecast
Average Price Target
$19.00
▲(117.14% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Bioxcel Therapeutics
―
Mereo Biopharma Group Plc
―
Kala Pharmaceuticals
―
Best Analysts Covering CADL
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+277.46%
reiterated a buy rating 5 days ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +277.46% per trade.
---